PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsRifaximin
Rifaximin
Xifaxan (rifaximin) is a small molecule pharmaceutical. Rifaximin was first approved as Xifaxan on 2004-05-25. It is used to treat bacterial infections, diarrhea, and irritable bowel syndrome in the USA.
Download report
Favorite
Top 200 Pharmaceuticals by Retail Sales
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
digestive system diseasesD004066
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
Xifaxan
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Rifaximin
Tradename
Company
Number
Date
Products
XIFAXANSalix PharmaceuticalsN-021361 RX2004-05-25
2 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
xifaxanNew Drug Application2025-08-27
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
irritable bowel syndromeEFO_0000555D043183K58
diarrhea—D003967R19.7
bacterial infections—D001424A49
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent
Expires
Flag
FDA Information
Rifaximin, Xifaxan, Salix Pharms
86425732029-10-02U-1481
89693982029-10-02U-1481
79281152029-07-24U-1121
88290172029-07-24U-1562
89462522029-07-24U-1481
94211952029-07-24U-1481
96298282029-07-24U-1994
103148282029-07-24U-1481
103353972029-07-24U-2579
107096942029-07-24U-2579
83095692029-07-18U-1707, U-1708
104563842029-02-26U-2643, U-2644
107656672029-02-26U-2643, U-2644
115649122029-02-26U-3511, U-3512
117795712029-02-26U-3706
81931962027-09-02DS, DPU-1707, U-1708
85189492026-02-27DP
87419042026-02-27DPU-1526, U-1707, U-1708
92719682026-02-27DP
107037632026-02-27U-1708, U-2847, U-2848
79065422025-06-01DS, DP
79152752025-02-23U-1707, U-1708
70456202024-06-19DS, DP
76121992024-06-19DS, DP
79022062024-06-19DS, DP
81586442024-06-19DP
81587812024-06-19DP
88354522024-06-19DS, DP
88532312024-06-19DP
ATC Codes
A: Alimentary tract and metabolism drugs
— A07: Antidiarrheals, intestinal antiinflammatory/antiinfective agents
— A07A: Intestinal antiinfectives
— A07AA: Antibiotics, intestinal
— A07AA11: Rifaximin
D: Dermatologicals
— D06: Antibiotics and chemotherapeutics for dermatological use
— D06A: Antibiotics for topical use
— D06AX: Other antibiotics for topical use in atc
— D06AX11: Rifaximin
HCPCS
No data
Clinical
Clinical Trials
213 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Hepatic encephalopathyD006501—K72.913510111240
Liver cirrhosisD008103EFO_0001422K74.0—1012101239
FibrosisD005355——110771029
DiarrheaD003967—R19.714116525
Irritable bowel syndromeD043183EFO_0000555K582856623
Brain diseasesD001927—G93.401224312
Liver diseasesD008107EFO_0001421K70-K77———426
AscitesD001201—R18——41—5
InflammationD007249MP_0001845—1411—5
Hepatic insufficiencyD048550—————5—5
Show 22 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Crohn diseaseD003424EFO_0000384K50174——11
Parkinson diseaseD010300EFO_0002508G20342——6
Abdominal painD015746EFO_0003766R10.9—13—25
RecurrenceD012008———12—14
Inflammatory bowel diseasesD015212EFO_0003767——32——3
DyspepsiaD004415EFO_0008533K30—21—13
Digestive system diseasesD004066EFO_0000405K92.9—11—23
Rectal neoplasmsD012004——111—13
DysenteryD004403EFO_1001869——11—12
Microscopic colitisD046728EFO_1001295K52.83—11——2
Show 15 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
SyndromeD013577——12——24
ObesityD009765EFO_0001073E66.911——13
RosaceaD012393—L71—3———3
AdenocarcinomaD000230——11——12
Intestinal pseudo-obstructionD007418EFO_1000988K56.0—1——12
NeoplasmsD009369—C8021———2
Alzheimer diseaseD000544EFO_0000249F0312———2
Sickle cell anemiaD000755EFO_0000697D57—2———2
Heart failureD006333EFO_0003144I50—1——12
Breast neoplasmsD001943EFO_0003869C50—1———1
Show 16 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Diabetes mellitusD003920EFO_0000400E08-E131————1
Chronic kidney failureD007676EFO_0003884N18.61————1
PharmacokineticsD010599——1————1
Persian gulf syndromeD018923EFO_0007430—1————1
Bone marrow transplantationD016026——1————1
ConstipationD003248—K59.01————1
DyskinesiasD020820—G241————1
Waldenstrom macroglobulinemiaD008258—C88.01————1
ParaproteinemiasD010265—D47.21————1
Communicable diseasesD003141——1————1
Show 2 more
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Colonic neoplasmsD003110—C18————22
Fatty liverD005234EFO_0003934—————22
Gastrointestinal diseasesD005767——————22
Gastrointestinal hemorrhageD006471—K92.2————22
Esophageal and gastric varicesD004932EFO_0009545I85————22
FeverD005334—R50.9————11
HyperthermiaD000084462——————11
Ulcerative colitisD003093EFO_0000729K51————11
ColitisD003092EFO_0003872K52.9————11
UlcerD014456MPATH_579—————11
Show 23 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameRifaximin
INNrifaximin
Description
Rifaximin is a semisynthetic member of the class of rifamycins and non-systemic gastrointestinal site-specific broad spectrum antibiotic. Used in the treatment of traveller's diarrhoea, hepatic encephalopathy and irritable bowel syndrome. It has a role as a gastrointestinal drug, an orphan drug and an antimicrobial agent. It is a member of rifamycins, an acetate ester, a lactam, an organic heterohexacyclic compound, a macrocycle, a semisynthetic derivative and a cyclic ketal.
Classification
Small molecule
Drug classantibiotics (rifamycin derivatives)
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
CO[C@H]1/C=C/O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(c5c(nc6cc(C)ccn65)c4c3C2=O)NC(=O)/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C
Identifiers
PDB—
CAS-ID80621-81-4
RxCUI—
ChEMBL IDCHEMBL1617
ChEBI ID75246
PubChem CID6436173
DrugBankDB01220
UNII IDL36O5T016N (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Rifaximin
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 7,626 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
14,367 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use